(Q35193420)

7 August 2017

1 reference

title

Methods of ensuring vaccine safety (English)

1 reference

7 August 2017

1 reference

Robert Ball

1

1 reference

7 August 2017

publication date

1 August 2002

1 reference

Expert Review of Vaccines

7 August 2017

published in

1 reference

7 August 2017

volume

1

1 reference

7 August 2017

issue

2

1 reference

7 August 2017

page(s)

161-168

1 reference

Evidence based vaccinology

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

The mumps virus neurovirulence safety test in Rhesus monkeys: a comparison of mumps virus strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

Safety considerations for new vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

Evaluating the safety of combination vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

Descriptive epidemiology of adverse events after immunization: reports to the Vaccine Adverse Event Reporting System (VAERS), 1991-1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

Principles of signal detection in pharmacovigilance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

Recombinant hepatitis B vaccination of neonates and infants: emerging safety data from the Vaccine Adverse Event Reporting System

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

Two-year review of hepatitis A vaccine safety: data from the Vaccine Adverse Event Reporting System (VAERS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

Postlicensure safety surveillance for varicella vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

The epidemiology of fatalities reported to the vaccine adverse event reporting system 1990-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

Population-based study of rotavirus vaccination and intussusception

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

Risk of chronic arthropathy among women after rubella vaccination. Vaccine Safety Datalink Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

Does influenza vaccination exacerbate asthma? Analysis of a large cohort of children with asthma. Vaccine Safety Datalink Team.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

Live attenuated polio vaccine and the risk of intussusception

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

Hepatitis B vaccination and the risk of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

Perspectives on the design and analysis of prelicensure trials: bridging the gap to postlicensure studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

Pharmacogenetics and pharmacoepidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

The reporting sensitivities of two passive surveillance systems for vaccine adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.1.2.161

21 January 2018

Identifiers

DOI

10.1586/14760584.1.2.161

1 reference

7 August 2017

1 reference